NEW YORK (GenomeWeb News) — Nanotechnology shop Lumera has spun out a company that will compete in the proteomics tools market, Lumera said yesterday.
 
The company, Plexera Bioscience, has become a wholly owned subsidiary of Lumera and will serve as the operations unit of Lumera's bioscience business that it started in 2006.
 
Plexera will focus on providing “tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers,” Lumera said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.